Artal Group S.A. held its position in Minerva Neurosciences, Inc (NASDAQ:NERV) during the second quarter, according to the company in its most recent filing with the SEC. The firm owned 251,300 shares of the biopharmaceutical company’s stock at the close of the second quarter. Artal Group S.A. owned approximately 0.68% of Minerva Neurosciences worth $2,224,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of NERV. Citadel Advisors LLC bought a new position in shares of Minerva Neurosciences during the 1st quarter worth approximately $110,000. Nationwide Fund Advisors boosted its holdings in shares of Minerva Neurosciences by 14.2% during the 2nd quarter. Nationwide Fund Advisors now owns 13,005 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,616 shares in the last quarter. Russell Investments Group Ltd. boosted its holdings in shares of Minerva Neurosciences by 54.6% during the 2nd quarter. Russell Investments Group Ltd. now owns 15,794 shares of the biopharmaceutical company’s stock worth $140,000 after buying an additional 5,579 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Minerva Neurosciences during the 2nd quarter worth approximately $159,000. Finally, Alpine Woods Capital Investors LLC boosted its holdings in shares of Minerva Neurosciences by 100.0% during the 2nd quarter. Alpine Woods Capital Investors LLC now owns 20,000 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 10,000 shares in the last quarter. Hedge funds and other institutional investors own 69.29% of the company’s stock.
A number of equities analysts have issued reports on the company. JMP Securities restated an “outperform” rating and set a $20.00 price target (up from $17.00) on shares of Minerva Neurosciences in a report on Thursday, June 1st. ValuEngine cut Minerva Neurosciences from a “sell” rating to a “strong sell” rating in a report on Monday, May 29th. BidaskClub cut Minerva Neurosciences from a “hold” rating to a “sell” rating in a report on Monday, July 24th. Zacks Investment Research upgraded Minerva Neurosciences from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a report on Wednesday, September 13th. Finally, Citigroup Inc. assumed coverage on Minerva Neurosciences in a report on Friday, September 1st. They set a “buy” rating and a $11.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $13.94.
COPYRIGHT VIOLATION NOTICE: “Artal Group S.A. Holds Stake in Minerva Neurosciences, Inc (NERV)” was originally reported by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/09/20/artal-group-s-a-holds-stake-in-minerva-neurosciences-inc-nerv.html.
Minerva Neurosciences, Inc (NASDAQ:NERV) traded down 0.68% during trading on Wednesday, hitting $7.30. The company’s stock had a trading volume of 94,743 shares. Minerva Neurosciences, Inc has a 12 month low of $5.55 and a 12 month high of $14.92. The firm has a 50 day moving average of $6.57 and a 200 day moving average of $7.76. The firm’s market cap is $310.32 million.
Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.07. During the same period in the previous year, the firm earned ($0.18) EPS. Equities research analysts predict that Minerva Neurosciences, Inc will post ($0.90) earnings per share for the current year.
Minerva Neurosciences Profile
Minerva Neurosciences, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio and indications include MIN-101 for the treatment of schizophrenia; MIN-202, for the treatment of insomnia disorder and major depressive disorder (MDD); MIN-117, for the treatment of MDD, and MIN-301 for the treatment of Parkinson’s disease.
Receive News & Ratings for Minerva Neurosciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences Inc and related companies with MarketBeat.com's FREE daily email newsletter.